BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 41 found
  Current Search:  endotoxemia: 41     

HTML
100%
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin
- Spectral Diagnostics Inc.

announced that the U.S.

Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Toraymyxin(TM), a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing...

Bionity.com:  Mar 8 2010 1:25PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

KSLA:  Mar 6 2010 8:45PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /CNW/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for...

Financials.com:  Mar 5 2010 1:36AM
Matching: endotoxemia
Find similar documents
HTML
100%
3/3/10 - BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing f
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Pharmacy Choice:  Mar 4 2010 10:40PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

KOTA Territory News:  Mar 4 2010 6:48PM
Matching: endotoxemia
Find similar documents
HTML
100%
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
TORONTO, March 2 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.

(TSX:SDI), a company developing products for the treatment of sepsis, today announced that the U.S.

Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE)...

KOTA Territory News:  Mar 4 2010 6:46PM
Matching: endotoxemia
Find similar documents
HTML
100%
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
TORONTO, March 2 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.

(TSX:SDI), a company developing products for the treatment of sepsis, today announced that the U.S.

Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE)...

PR Newswire:  Mar 4 2010 6:14PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Pharmacy Choice:  Mar 4 2010 8:19AM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /CNW/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI)...

Canada NewsWire:  Mar 3 2010 4:38PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

San Jose Business Journal:  Mar 3 2010 1:56PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Wichita Business Journal:  Mar 3 2010 1:47PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Birmingham Business Journal:  Mar 3 2010 1:44PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Business Journal of Milwaukee:  Mar 3 2010 1:41PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Toronto Stock Exchange Symbol: MS Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million.

BioMS subscribed to 30,000,000 of the units.

The EUPHRATES ...

TradingMarkets:  Mar 3 2010 1:41PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

FOXBusiness.com:  Mar 3 2010 1:39PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Toronto Stock Exchange Symbol: MS Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million.

BioMS subscribed to 30,000,000 of the units.

The EUPHRATES ...

TradingMarkets:  Mar 3 2010 1:39PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Austin Business Journal:  Mar 3 2010 1:38PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Dallas Business Chronicle:  Mar 3 2010 1:35PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Cincinnati Business Journal:  Mar 3 2010 1:27PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

San Francisco Business Times:  Mar 3 2010 1:27PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

Memphis Business Journal:  Mar 3 2010 1:25PM
Matching: endotoxemia
Find similar documents
HTML
100%
Spectral Diagnostics receives FDA IDE approval for Toraymyxin
BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug Administration (FDA) for Toraymyxin(TM).

Spectral Diagnostics and BioMS have entered...

News-Medical.Net:  Mar 3 2010 1:10PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /CNW/ - BioMS Medical Corp.

(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI)...

CNW Telbec:  Mar 3 2010 1:09PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing
Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.

Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million.

Interest!ALERT:  Mar 3 2010 1:08PM
Matching: endotoxemia
Find similar documents
HTML
100%
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.

(TSX:MS) today reported that Spectral Diagnostics (TSX:SDI) has received Investigational Device Exemption (IDE) approval from the U.S.

Food and Drug...

Houston Chronicle:  Mar 3 2010 1:06PM
Matching: endotoxemia
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.